Скачать или смотреть AngioDynamics, Inc. (NASDAQ: ANGO) Q1 2026 Earnings Call | 10/02/2025Description:

AngioDynamics, Inc. (NASDAQ: ANGO) reported a strong start to fiscal 2026 with total revenue of $75.7 million, marking a 12.2% year-over-year increase, driven primarily by a 26.1% surge in the Med Tech segment to $35.3 million. The Med Device segment grew modestly by 2.3% to $40.4 million. Key product lines such as Auryon, Mechanical Thrombectomy platforms (AngioVac and AlphaVac), and NanoKnife continued to show robust double-digit growth, reflecting expanding market adoption and clinical application.

Gross margin improved by 90 basis points to 55.3%, although tariff expenses impacted margins by approximately 220 basis points. The company reported a GAAP loss of $10.9 million ($0.26 per share), down from a $12.8 million loss the prior year. Adjusted net loss was $4.2 million ($0.10 per share), slightly better than earlier expectations. Adjusted EBITDA improved to $2.2 million from a loss of $152,000 in the same quarter last year.

AngioDynamics maintained a strong balance sheet with $38.8 million in cash and no debt as of August 31, 2025. The company raised its full-year 2026 revenue guidance to $308 million to $313 million and forecasted Med Tech segment growth of 14% to 16%. Adjusted EBITDA and loss per share guidance were also improved, reflecting confidence in ongoing operational execution and market expansion. Management expects positive free cash flow for the full fiscal year.

Strategic initiatives include advancing the Auryon platform and pivotal clinical trials in peripheral artery disease, alongside innovation in cancer and thrombectomy treatment technologies. Despite tariff-related challenges and cash utilization in Q1, AngioDynamics' focused Med Tech growth and pipeline investments position it well for sustainable long-term growth.

About Inside Ticker:
Inside Ticker provides clear, timely, and professional coverage of earnings reports, market updates, and financial insights. Stay informed with in-depth analysis at https://www.insideticker.com/.

HashTags:
#AngioDynamics #ANGO #Q12026 #Earnings #FinancialResults #Revenue #NetLoss #EPS #MedTech #MedDevice #Auryon #MechanicalThrombectomy #AngioVac #AlphaVac #NanoKnife #ClinicalTrials #PeripheralArteryDisease #CancerTreatment #GrossMargin #AdjustedEBITDA #CashFlow #Tariffs #RevenueGuidance #Innovation #MedicalDevices #StockMarket #InsideTicker #QuarterlyResults #Profitability #InvestorUpdate